Medicine
Volume 36, Issue 1 , Pages 24-28 , January 2008

Cytotoxic chemotherapy: clinical aspects

References 

  1. Clark P. Surgical resection with or without pre-operative chemotherapy in oesophageal cancer: an updated analysis of a randomised controlled trial conducted by the UK Medical Research Council Upper GI Tract Cancer Group. Lancet. 2002;359:1727–1733
  2. Travis LB, Rabkin CS, Brown LM, et al. Cancer survivorship—genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst. 2006;98:15–25
  3. Allan JM, Travis LB. Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer. 2005;5:943–955
  4. Matesich SM, Shapiro CL. Second cancers after breast cancer treatment. Semin Oncol. 2003;30:740–748
  5. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. New Eng Med J. 2006;355:1572–1582
  6. National Institute for Health and Clinical Excellence . Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer. Technology Appraisal 61. London: NICE; May 2003;
  7. National Institute for Clinical Excellence . Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer. Technology Appraisal 62. London: NICE; May 2003;
  8. Weingart SN, Flug J, Brouillard D, et al. Oral chemotherapy safety practices at US cancer centres: questionnaire survey. BMJ. 2007;334:407–409
  9. Department of Health . National guidance on the safe administration of intrathecal chemotherapy. London: DoH; Oct 2003;(HSC 2003/010). Available at: http://www.dh.gov.uk
  10. Hamilton CA, Berek JS. Intraperitoneal chemotherapy for ovarian cancer. Curr Opin Oncol. 2006;18:507–515
  11. Kerr DJ, McArdle CS, Ledermann J, et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet. 2003;361:368–373
  12. Nobili S, Landini I, Giglioni B, Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets. 2006;7:861–879
  13. Quintieri L, Fantin M, Vizler C. Identification of molecular determinants of tumour sensitivity and resistance to anticancer drugs. Adv Exp Med Biol. 2007;593:95–104
  14. Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003;362:362–369
  15. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cell. Nature. 2001;414:105–111
  16. Yilmaz ÖH, Valdez R, Theisen BK, et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature. 2006;441:475–482

PII: S1357-3039(07)00349-0

doi: 10.1016/j.mpmed.2007.10.012

Medicine
Volume 36, Issue 1 , Pages 24-28 , January 2008

Article Tools

* Image Usage & Resolution